サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1402917

ワクチン市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年

Vaccines Market (Vaccine: Inactivated, Live Attenuated, Toxoid, Conjugate, and Others; and Valance: Monovalent and Multivalent) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 289 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.36円
ワクチン市場：世界の業界分析、規模、シェア、成長、動向、予測、2023～2031年
出版日: 2023年11月22日
発行: Transparency Market Research
ページ情報: 英文 289 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ワクチン市場- レポートの範囲

世界のワクチン市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、2023年を基準年、2031年を予測年とみなし、2017年から2031年までの世界のワクチン市場の収益を提供します。レポートは、2023年から2031年までの世界のワクチン市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、ワクチン市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 1,191億米ドル
2031年の市場価値 993億米ドル
CAGR 4.2%

このレポートは、世界のワクチン市場の競合情勢を詳しく調査しています。世界のワクチン市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界のワクチン市場のプレーヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 意味
  • 業界の進化/発展
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

第6章 世界市場分析と予測：ワクチン別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：ワクチン別、2017-2031
    • 不活化ワクチン
    • 弱毒生ワクチン
    • トキソイド
    • コンジュゲートワクチン
    • その他
  • 市場魅力度分析：ワクチン別

第7章 世界市場の分析と予測：価数別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：価数別、2017-2031
    • 一価
    • 多価
  • 市場魅力度分析：価数別

第8章 世界市場の分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：投与経路別、2017-2031
    • 経口
    • 注射用
    • その他
  • 市場魅力度分析：投与経路別

第9章 世界市場の分析と予測：適応症別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：適応症別、2017-2031
    • インフルエンザ
    • 肝炎
    • ポリオ
    • 髄膜炎菌性疾患
    • 肺炎球菌疾患
    • DTP
    • ロタウイルス
    • MMR
    • ヒトパピローマウイルス
    • その他
  • 市場魅力度分析：適応症別

第10章 世界市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：流通チャネル別、2017-2031
    • 機関販売
    • 病院薬局
    • 小売薬局
  • 市場魅力度分析：流通チャネル別

第11章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017-2031
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第12章 北米市場の分析と予測

第13章 欧州市場の分析と予測

第14章 アジア太平洋市場の分析と予測

第15章 ラテンアメリカ市場の分析と予測

第16章 中東・アフリカ市場の分析と予測

第17章 競合情勢

  • 市場プレーヤーの競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • AstraZeneca
    • GlaxoSmithKline PLC
    • Sanofi Pasteur SA
    • Pfizer Inc.
    • Panacea Biotec
    • Merck &Co., Inc.
    • Janssen Pharmaceutical Company
    • Serus Institute of India Ltd
    • Emergent BioSolutions Inc.
    • CSL
    • Bavarian Nordic
    • IBSS BIOMED SA
    • Novavax AB
    • Mitsubishi Tanabe Pharma Corporation
図表

List of Tables

  • Table 01. Global Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
  • Table 02. Global Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
  • Table 03. Global Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 04. Global Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 05. Global Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 06. Global Vaccines Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 07. North America Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
  • Table 08. North America Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
  • Table 09. North America Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 10. North America Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 11. North America Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12. Europe Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13. Europe Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
  • Table 14. Europe Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
  • Table 15. Europe Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16. Europe Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 17. Europe Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 19. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
  • Table 20. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
  • Table 21. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 22. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 23. Asia Pacific Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 24. Latin America Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 25. Latin America Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
  • Table 26. Latin America Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
  • Table 27. Latin America Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 28. Latin America Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 29. Latin America Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 30. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 31. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Vaccine, 2017-2031
  • Table 32. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Valance, 2017-2031
  • Table 33. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 34. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 35. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01. Global Vaccines Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02. Vaccines Market Value Share, by Vaccine, 2022
  • Figure 03. Vaccines Market Value Share, by Valance, 2022
  • Figure 04. Vaccines Market Value Share, by Route of Administration, 2022
  • Figure 05. Vaccines Market Value Share, by Indication, 2022
  • Figure 06. Vaccines Market Value Share, by Distribution Channel, 2022
  • Figure 07. Global Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
  • Figure 08. Global Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
  • Figure 09. Global Vaccines Market Value Share Analysis, by Valance 2022 and 2031
  • Figure 10. Global Vaccines Market Attractiveness Analysis, Valance, 2023-2031
  • Figure 11. Global Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
  • Figure 12. Global Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
  • Figure 13. Global Vaccines Market Value Share Analysis, by Indication 2022 and 2031
  • Figure 14. Global Vaccines Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 15. Global Vaccines Market Value Share Analysis, by Distribution Channel 2022 and 2031
  • Figure 16. Global Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
  • Figure 17. Global Vaccines Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 18. Global Vaccines Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 19. North America Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 20. North America Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
  • Figure 21. North America Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
  • Figure 22. North America Vaccines Market Value Share Analysis, by Valance 2022 and 2031
  • Figure 23. North America Vaccines Market Attractiveness Analysis, Valance, 2023-2031
  • Figure 24. North America Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
  • Figure 25. North America Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
  • Figure 26. North America Vaccines Market Value Share Analysis, by Indication 2022 and 2031
  • Figure 27. North America Vaccines Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 28. North America Vaccines Market Value Share Analysis, by Distribution Channel 2022 and 2031
  • Figure 29. North America Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
  • Figure 30. Europe Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 31. Europe Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 32. Europe Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 33. Europe Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
  • Figure 34. Europe Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
  • Figure 35. Europe Vaccines Market Value Share Analysis, by Valance, 2022 and 2031
  • Figure 36. Europe Vaccines Market Attractiveness Analysis, Valance, 2023-2031
  • Figure 37. Europe Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
  • Figure 38. Europe Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
  • Figure 39. Europe Vaccines Market Value Share Analysis, by Indication 2022 and 2031
  • Figure 40. Europe Vaccines Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 41. Europe Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 42. Europe Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
  • Figure 43. Asia Pacific Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 44. Asia Pacific Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 45. Asia Pacific Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 46. Asia Pacific Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
  • Figure 47. Asia Pacific Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
  • Figure 48. Asia Pacific Vaccines Market Value Share Analysis, by Valance, 2022 and 2031
  • Figure 49. Asia Pacific Vaccines Market Attractiveness Analysis, Valance, 2023-2031
  • Figure 50. Asia Pacific Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
  • Figure 51. Asia Pacific Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
  • Figure 52. Asia Pacific Vaccines Market Value Share Analysis, by Indication 2022 and 2031
  • Figure 53. Asia Pacific Vaccines Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 54. Asia Pacific Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 55. Asia Pacific Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
  • Figure 56. Latin America Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 57. Latin America Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 58. Latin America Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 59. Latin America Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
  • Figure 60. Latin America Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
  • Figure 61. Latin America Vaccines Market Value Share Analysis, by Valance, 2022 and 2031
  • Figure 62. Latin America Vaccines Market Attractiveness Analysis, Valance, 2023-2031
  • Figure 63. Latin America Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
  • Figure 64. Latin America Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
  • Figure 65. Latin America Vaccines Market Value Share Analysis, by Indication 2022 and 2031
  • Figure 66. Latin America Vaccines Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 67. Latin America Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 68. Latin America Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
  • Figure 69. Middle East & Africa Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 70. Middle East & Africa Vaccines Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 71. Middle East & Africa Vaccines Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 72. Middle East & Africa Vaccines Market Value Share Analysis, by Vaccine 2022 and 2031
  • Figure 73. Middle East & Africa Vaccines Market Attractiveness Analysis, Vaccine, 2023-2031
  • Figure 74. Middle East & Africa Vaccines Market Value Share Analysis, by Valance, 2022 and 2031
  • Figure 75. Middle East & Africa Vaccines Market Attractiveness Analysis, Valance, 2023-2031
  • Figure 76. Middle East & Africa Vaccines Market Value Share Analysis, by Route of Administration 2022 and 2031
  • Figure 77. Middle East & Africa Vaccines Market Attractiveness Analysis, Route of Administration, 2023-2031
  • Figure 78. Middle East & Africa Vaccines Market Value Share Analysis, by Indication 2022 and 2031
  • Figure 79. Middle East & Africa Vaccines Market Attractiveness Analysis, Indication, 2023-2031
  • Figure 80. Middle East & Africa Vaccines Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 81. Middle East & Africa Vaccines Market Attractiveness Analysis, Distribution Channel, 2023-2031
目次
Product Code: TMRGL21

Vaccines Market - Scope of Report

TMR's report on the global vaccines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global vaccines market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global vaccines market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the vaccines market.

Market Snapshot
Market Value in 2023US$ 119.1 Bn
Market Value in 2031US$ 99.3 Bn
CAGR4.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global vaccines market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global vaccines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global vaccines market.

The report delves into the competitive landscape of the global vaccines market. Key players operating in the global vaccines market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global vaccines market profiled in this report.

Key Questions Answered in Global vaccines Market Report:

  • What is the sales/revenue generated by vaccines across all regions during the forecast period?
  • What are the opportunities in the global vaccines market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Vaccines Market - Research Objectives and Research Approach

The comprehensive report on the global vaccines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global vaccines market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global vaccines market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Vaccines Market

4. Market Overview

  • 4.1. Introduction
  • 4.2. Definition
  • 4.3. Industry Evolution / Developments
  • 4.4. Overview
  • 4.5. Market Dynamics
    • 4.5.1. Drivers
    • 4.5.2. Restraints
    • 4.5.3. Opportunities
  • 4.6. Global Vaccines Market Analysis and Forecast, 2017-2031
    • 4.6.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Regulatory Scenario
  • 5.2. Key Distribution Strategies
  • 5.3. Pricing Analysis
  • 5.4. Patents on Vaccines
  • 5.5. Technological Advancements in Vaccines
  • 5.6. Vaccine Type - Overview
  • 5.7. COVID-19 Pandemic Impact on Industry

6. Global Vaccines Market Analysis and Forecast, by Vaccine

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Vaccine, 2017-2031
    • 6.3.1. Inactivated
    • 6.3.2. Live Attenuated
    • 6.3.3. Toxoid
    • 6.3.4. Conjugate
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Vaccine

7. Global Vaccines Market Analysis and Forecast, by Valance

  • 7.1. Introduction & Definition
  • 7.2. Developments
  • 7.3. Market Value Forecast, by Valance, 2017-2031
    • 7.3.1. Monovalent
    • 7.3.2. Multivalent
  • 7.4. Market Attractiveness Analysis, by Valance

8. Global Vaccines Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 8.3.1. Oral
    • 8.3.2. Injectable
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Vaccines Market Analysis and Forecast, by Indication

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Indication, 2017-2031
    • 9.3.1. Influenza
    • 9.3.2. Hepatitis
    • 9.3.3. Polio
    • 9.3.4. Meningococcal Disease
    • 9.3.5. Pneumococcal Disease
    • 9.3.6. DTP
    • 9.3.7. Rotavirus
    • 9.3.8. MMR
    • 9.3.9. Human Papilloma Virus
    • 9.3.10. Others
  • 9.4. Market Attractiveness Analysis, by Indication

10. Global Vaccines Market Analysis and Forecast, by Distribution Channel

  • 10.1. Introduction & Definition
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.3.1. Institutional Sales
    • 10.3.2. Hospital Pharmacies
    • 10.3.3. Retail Pharmacies
  • 10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Vaccines Market Analysis and Forecast, by Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast, by Region, 2017-2031
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness Analysis, by Region

12. North America Vaccines Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Vaccine, 2017-2031
    • 12.3.1. Inactivated
    • 12.3.2. Live Attenuated
    • 12.3.3. Toxoid
    • 12.3.4. Conjugate
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Valance, 2017-2031
    • 12.4.1. Monovalent
    • 12.4.2. Multivalent
  • 12.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.5.1. Oral
    • 12.5.2. Injectable
    • 12.5.3. Others
  • 12.6. Market Value Forecast, by Indication, 2017-2031
    • 12.6.1. Influenza
    • 12.6.2. Hepatitis
    • 12.6.3. Polio
    • 12.6.4. Meningococcal Disease
    • 12.6.5. Pneumococcal Disease
    • 12.6.6. DTP
    • 12.6.7. Rotavirus
    • 12.6.8. MMR
    • 12.6.9. Human Papilloma Virus
    • 12.6.10. Others
  • 12.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.7.1. Institutional Sales
    • 12.7.2. Hospital Pharmacies
    • 12.7.3. Retail Pharmacies
  • 12.8. Market Value Forecast, by Country/sub-region, 2017-2031
    • 12.8.1. U.S.
    • 12.8.2. Canada
  • 12.9. Market Attractiveness Analysis
    • 12.9.1. By Vaccine
    • 12.9.2. By Valance
    • 12.9.3. By Route of Administration
    • 12.9.4. By Indication
    • 12.9.5. By Distribution Channel
    • 12.9.6. By Country

13. Europe Vaccines Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Vaccine, 2017-2031
    • 13.3.1. Inactivated
    • 13.3.2. Live Attenuated
    • 13.3.3. Toxoid
    • 13.3.4. Conjugate
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Valance, 2017-2031
    • 13.4.1. Monovalent
    • 13.4.2. Multivalent
  • 13.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.5.1. Oral
    • 13.5.2. Injectable
    • 13.5.3. Others
  • 13.6. Market Value Forecast, by Indication, 2017-2031
    • 13.6.1. Influenza
    • 13.6.2. Hepatitis
    • 13.6.3. Polio
    • 13.6.4. Meningococcal Disease
    • 13.6.5. Pneumococcal Disease
    • 13.6.6. DTP
    • 13.6.7. Rotavirus
    • 13.6.8. MMR
    • 13.6.9. Human Papilloma Virus
    • 13.6.10. Others
  • 13.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.7.1. Institutional Sales
    • 13.7.2. Hospital Pharmacies
    • 13.7.3. Retail Pharmacies
  • 13.8. Market Value Forecast, by Country/sub-region, 2017-2031
    • 13.8.1. Germany
    • 13.8.2. U.K.
    • 13.8.3. France
    • 13.8.4. Italy
    • 13.8.5. Spain
    • 13.8.6. Rest of Europe
  • 13.9. Market Attractiveness Analysis
    • 13.9.1. By Vaccine
    • 13.9.2. By Valance
    • 13.9.3. By Route of Administration
    • 13.9.4. By Indication
    • 13.9.5. By Distribution Channel
    • 13.9.6. By Country/Sub-region

14. Asia Pacific Vaccines Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Vaccine, 2017-2031
    • 14.3.1. Inactivated
    • 14.3.2. Live Attenuated
    • 14.3.3. Toxoid
    • 14.3.4. Conjugate
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Valance, 2017-2031
    • 14.4.1. Monovalent
    • 14.4.2. Multivalent
  • 14.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.5.1. Oral
    • 14.5.2. Injectable
    • 14.5.3. Others
  • 14.6. Market Value Forecast, by Indication, 2017-2031
    • 14.6.1. Influenza
    • 14.6.2. Hepatitis
    • 14.6.3. Polio
    • 14.6.4. Meningococcal Disease
    • 14.6.5. Pneumococcal Disease
    • 14.6.6. DTP
    • 14.6.7. Rotavirus
    • 14.6.8. MMR
    • 14.6.9. Human Papilloma Virus
    • 14.6.10. Others
  • 14.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.7.1. Institutional Sales
    • 14.7.2. Hospital Pharmacies
    • 14.7.3. Retail Pharmacies
  • 14.8. Market Value Forecast, by Country/sub-region, 2017-2031
    • 14.8.1. China
    • 14.8.2. India
    • 14.8.3. Japan
    • 14.8.4. Australia & New Zealand
    • 14.8.5. Rest of Asia Pacific
  • 14.9. Market Attractiveness Analysis
    • 14.9.1. By Vaccine
    • 14.9.2. By Valance
    • 14.9.3. By Route of Administration
    • 14.9.4. By Indication
    • 14.9.5. By Distribution Channel
    • 14.9.6. By Country/Sub-region

15. Latin America Vaccines Market Analysis and Forecast

  • 15.1. Introduction
  • 15.2. Key Findings
  • 15.3. Market Value Forecast, by Vaccine, 2017-2031
    • 15.3.1. Inactivated
    • 15.3.2. Live Attenuated
    • 15.3.3. Toxoid
    • 15.3.4. Conjugate
    • 15.3.5. Others
    • 15.3.6. Others
  • 15.4. Market Value Forecast, by Valance, 2017-2031
    • 15.4.1. Monovalent
    • 15.4.2. Multivalent
  • 15.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 15.5.1. Oral
    • 15.5.2. Injectable
    • 15.5.3. Others
  • 15.6. Market Value Forecast, by Indication, 2017-2031
    • 15.6.1. Influenza
    • 15.6.2. Hepatitis
    • 15.6.3. Polio
    • 15.6.4. Meningococcal Disease
    • 15.6.5. Pneumococcal Disease
    • 15.6.6. DTP
    • 15.6.7. Rotavirus
    • 15.6.8. MMR
    • 15.6.9. Human Papilloma Virus
    • 15.6.10. Others
  • 15.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 15.7.1. Institutional Sales
    • 15.7.2. Hospital Pharmacies
    • 15.7.3. Retail Pharmacies
  • 15.8. Market Value Forecast, by Country/sub-region, 2017-2031
    • 15.8.1. Brazil
    • 15.8.2. Mexico
    • 15.8.3. Rest of Latin America
  • 15.9. Market Attractiveness Analysis
    • 15.9.1. By Vaccine
    • 15.9.2. By Valance
    • 15.9.3. By Route of Administration
    • 15.9.4. By Indication
    • 15.9.5. By Distribution Channel
    • 15.9.6. By Country/Sub-region

16. Middle East & Africa Vaccines Market Analysis and Forecast

  • 16.1. Introduction
  • 16.2. Key Findings
  • 16.3. Market Value Forecast, by Vaccine, 2017-2031
    • 16.3.1. Inactivated
    • 16.3.2. Live Attenuated
    • 16.3.3. Toxoid
    • 16.3.4. Conjugate
    • 16.3.5. Others
  • 16.4. Market Value Forecast, by Valance, 2017-2031
    • 16.4.1. Monovalent
    • 16.4.2. Multivalent
  • 16.5. Market Value Forecast, by Route of Administration, 2017-2031
    • 16.5.1. Oral
    • 16.5.2. Injectable
    • 16.5.3. Others
  • 16.6. Market Value Forecast, by Indication, 2017-2031
    • 16.6.1. Influenza
    • 16.6.2. Hepatitis
    • 16.6.3. Polio
    • 16.6.4. Meningococcal Disease
    • 16.6.5. Pneumococcal Disease
    • 16.6.6. DTP
    • 16.6.7. Rotavirus
    • 16.6.8. MMR
    • 16.6.9. Human Papilloma Virus
    • 16.6.10. Others
  • 16.7. Market Value Forecast, by Distribution Channel, 2017-2031
    • 16.7.1. Institutional Sales
    • 16.7.2. Hospital Pharmacies
    • 16.7.3. Retail Pharmacies
  • 16.8. Market Value Forecast, by Country/sub-region, 2017-2031
    • 16.8.1. GCC Countries
    • 16.8.2. South Africa
    • 16.8.3. Rest of Middle East & Africa
  • 16.9. Market Attractiveness Analysis
    • 16.9.1. By Vaccine
    • 16.9.2. By Valance
    • 16.9.3. By Route of Administration
    • 16.9.4. By Indication
    • 16.9.5. By Distribution Channel
    • 16.9.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player Competition Matrix (by tier and size of companies)
  • 17.2. Market Share Analysis, by Company (2022)
  • 17.3. Company Profiles
    • 17.3.1. AstraZeneca
      • 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.1.2. Product Portfolio
      • 17.3.1.3. Financial Overview
      • 17.3.1.4. SWOT Analysis
      • 17.3.1.5. Strategic Overview
    • 17.3.2. GlaxoSmithKline PLC
      • 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.2.2. Product Portfolio
      • 17.3.2.3. Financial Overview
      • 17.3.2.4. SWOT Analysis
      • 17.3.2.5. Strategic Overview
    • 17.3.3. Sanofi Pasteur SA
      • 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.3.2. Product Portfolio
      • 17.3.3.3. Financial Overview
      • 17.3.3.4. SWOT Analysis
      • 17.3.3.5. Strategic Overview
    • 17.3.4. Pfizer Inc.
      • 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.4.2. Product Portfolio
      • 17.3.4.3. Financial Overview
      • 17.3.4.4. SWOT Analysis
      • 17.3.4.5. Strategic Overview
    • 17.3.5. Panacea Biotec
      • 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.5.2. Product Portfolio
      • 17.3.5.3. Financial Overview
      • 17.3.5.4. SWOT Analysis
      • 17.3.5.5. Strategic Overview
    • 17.3.6. Merck & Co., Inc.
      • 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.6.2. Product Portfolio
      • 17.3.6.3. Financial Overview
      • 17.3.6.4. SWOT Analysis
      • 17.3.6.5. Strategic Overview
    • 17.3.7. Janssen Pharmaceutical Company
      • 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.7.2. Product Portfolio
      • 17.3.7.3. Financial Overview
      • 17.3.7.4. SWOT Analysis
      • 17.3.7.5. Strategic Overview
    • 17.3.8. Serus Institute of India Ltd
      • 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.8.2. Product Portfolio
      • 17.3.8.3. Financial Overview
      • 17.3.8.4. SWOT Analysis
      • 17.3.8.5. Strategic Overview
    • 17.3.9. Emergent BioSolutions Inc.
      • 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.9.2. Product Portfolio
      • 17.3.9.3. Financial Overview
      • 17.3.9.4. SWOT Analysis
      • 17.3.9.5. Strategic Overview
    • 17.3.10. CSL
      • 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.10.2. Product Portfolio
      • 17.3.10.3. Financial Overview
      • 17.3.10.4. SWOT Analysis
      • 17.3.10.5. Strategic Overview
    • 17.3.11. Bavarian Nordic
      • 17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.11.2. Product Portfolio
      • 17.3.11.3. Financial Overview
      • 17.3.11.4. SWOT Analysis
      • 17.3.11.5. Strategic Overview
    • 17.3.12. IBSS BIOMED S.A.
      • 17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.12.2. Product Portfolio
      • 17.3.12.3. Financial Overview
      • 17.3.12.4. SWOT Analysis
      • 17.3.12.5. Strategic Overview
    • 17.3.13. Novavax AB
      • 17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.13.2. Product Portfolio
      • 17.3.13.3. Financial Overview
      • 17.3.13.4. SWOT Analysis
      • 17.3.13.5. Strategic Overview
    • 17.3.14. Mitsubishi Tanabe Pharma Corporation
      • 17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.14.2. Product Portfolio
      • 17.3.14.3. Financial Overview
      • 17.3.14.4. SWOT Analysis
      • 17.3.14.5. Strategic Overview